US Patent Issued to Ablynx, Sanofi on Dec. 30 for "Polypeptides comprising immunoglobulin single variable domains targeting il-13 and OX40L" (Belgian, German, American Inventors)

ALEXANDRIA, Va., Dec. 31 -- United States Patent no. 12,509,522, issued on Dec. 30, was assigned to Ablynx N.V. (Zwijnaarde, Belgium) and Sanofi (Paris).

"Polypeptides comprising immunoglobulin single variable domains targeting il-13 and OX40L" was invented by Heidi Rommelaere (Ghent, Belgium), Ann Brige (Ertvelde, Belgium), Sigrid Cornelis (Sint Martens-Latem, Belgium), Bruno Dombrecht (Heusden, Belgium), Klaus Erb (Ingelheim Am Rhein, Germany), Eric Lorent (Zwijnaarde, Belgium), John Park (Warthausen, Germany), Robert Resnick (Bridgewater, N.J.), Melanie Rieger (Zwijnaarde, Belgium) and Bernd Weigle (Ingelheim Am Rhein, Germany).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides ...